Abstract: The invention concerns an in-vitro method for introducing a targeted genome modification into an oocyte or an egg and a method for performing a random insertion in the genome of a host cell.
Type:
Grant
Filed:
June 13, 2007
Date of Patent:
October 27, 2015
Assignees:
Centre National de la Recherche Scientifique-CNRS, INSERM (Institut National de la Sante et de la Recherche Medicale), Universite d'Aix Marseille, Universite de Montpellier, Institut Regional du Cancer de Montpellier-Val d'Aurelle, Institut Paoli Calmettes
Inventors:
Daniel Baty, Ghislaine Behar, Martine Chartier, André Pelegrin, Jean-luc Teillaud, Isabelle Teulon
Abstract: The invention relates to bait formulations comprising at least one iron salt, at least one component selected from among methyl glycine-N,N-diacetic acid, glutamine-N,N-diacetic acid, and the alkali metal, alkaline earth metal and ammonium salts thereof; and at least one starch-containing component. The invention also relates to the use of said bait formulation for controlling terrestrial slugs and snails and to a method for controlling terrestrial slugs and snails using the bait formulation of the invention.
Abstract: Pharmaceutical foam compositions substantially free of ethanol and comprising pimecrolimus in a carrier vehicle comprising a mixture of oily solvents amounting to at least 40% of the total weight of the composition and consisting of: i) hexylene glycol; ii) optionally oleyl alcohol; and iii) dimethylisosorbide and/or medium chain triglycerides; and additionally: iv) when oleyl alcohol is absent, water in an amount of less than 25%; v) at least one consistency agent; vi) at least one preservative; and vii) at least one surfactant/emulgator; and propellant gas for foaming; and optionally further conventional excipients. They are indicated for use in the treatment of various skin, nail and mucosal diseases.
Type:
Grant
Filed:
April 7, 2005
Date of Patent:
October 27, 2015
Assignee:
Meda Pharma SARL
Inventors:
Meir Eini, Doron Friedman, Stefan Hirsch, Sabine Meyenburg, Nabila Sekkat, Dov Tamarkin
Abstract: A method for determining an expression of human epidermal growth factor receptor 2 (HER2) of a subject. The method includes providing a sample from the subject; measuring one of (i) amounts of two or more proteins in the sample, each protein having a molecular weight substantially equal to 4740, 8404, 8419, 8435, 8450, 8455, 8465, 8570, 8607 or 8626 atomic mass units, and (ii) amounts of at least one of human cystein-rich intestinal protein 1 (CRIP1), one or more variants of the human cystein-rich intestinal protein 1 (CRIP1 variants), and proteolytic digestion products thereof in the sample; and comparing the amounts of the proteins to control amounts, which control amounts are determinative of the expression of the human epidermal growth factor receptor 2.
Type:
Grant
Filed:
September 10, 2010
Date of Patent:
October 20, 2015
Assignee:
Bruker Daltonik GmbH
Inventors:
Christian Albers, Eckhard Belau, Sören-Oliver Deininger, Sandra Rauser, Detlev Suckau, Axel Walch
Abstract: The invention relates to antibodies or fragments thereof specific for insulin-like growth factor binding protein-7 (IGFBP7). A method of raising anti-IGFBP7 single domain antibodies is also disclosed and specific antibody clones are described, along with their binding characteristics. The anti-IGFBP7 antibodies may be useful as diagnostic tools for detecting neoplastic diseases involving tumor angiogenesis, and a variety of other angiogenesis associated diseases.
Type:
Grant
Filed:
October 14, 2009
Date of Patent:
October 20, 2015
Assignee:
National Research Council of Canada
Inventors:
Danica Stanimirovic, Abedelnasser Abulrob, Maria Moreno
Abstract: The present invention relates to a novel antigen-binding protein construct or “modubody”, which contains at least three functional single domain modules of an antibody. The modubodies contain a domain from the heavy chain variable region of an antibody (VH), a domain from the light chain variable region of an antibody (VL) and bind monospecifically to an antigen. The modubodies further contain a domain from the constant region of antibodies. The modubodies can be used for diagnostic or therapeutic purposes.
Abstract: The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering.
Abstract: A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient.
Abstract: Provided herein are methods for identifying a cancer patient at risk for resistance to an HDAC inhibitor therapy, comprising obtaining a tumor sample from the cancer patient; detecting the presence of Testis-specific Y-encoded-like protein 5 (TSPYL5) expression in the sample; quantifying a level of the TSPYL5 expression in the sample, wherein a high level of the TSPYL5 expression, relative to a defined expression threshold of the TSPYL5, correlates with resistance to the HDAC inhibitor therapy; and applying the correlation to identify the cancer patient at risk for resistance to the HDAC inhibitor therapy.
Abstract: An antibacterial imidazolium compound, a photocurable coating composition, and an antibacterial coating film includes a compound represented by Chemical Formula 1 shown below or derivatives thereof. In Chemical Formula 1, description of X?, R1 and, R2 is the same as in the detailed description of the invention. The antibacterial imidazolium compound has excellent antibiosis over various strains, and is included in a photocurable coating composition so as to provide an antibacterial coating film by a simple method. Also, in the antibacterial coating film, the antibacterial imidazolium compound is included as a monomer and chemically bonded to a polymer chain, and thus, antibacterial performance can be maintained for a long period of time.
Type:
Grant
Filed:
February 15, 2013
Date of Patent:
September 15, 2015
Assignee:
KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Abstract: The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate.
Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
Type:
Grant
Filed:
August 31, 2011
Date of Patent:
September 1, 2015
Assignee:
METHERESIS TRANSLATIONAL RESEARCH S.A.
Inventors:
Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria Comoglio
Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
Type:
Grant
Filed:
October 8, 2013
Date of Patent:
August 11, 2015
Assignee:
Immunomedics, Inc.
Inventors:
Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
Type:
Grant
Filed:
November 12, 2010
Date of Patent:
August 11, 2015
Assignees:
U3 Pharma GmbH, Amgen, Inc.
Inventors:
Thore Hettmann, Daniel J. Freeman, Robert Radinsky
Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
Abstract: The invention relates to a kit of parts, suitable for use in a therapy of cancer, wherein said kit comprises: (i) a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several tumor-associated antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells or a mixture of such recombinant proteins wherein at least one of said epitopes, or tumor associated antigens, or insertion sites of CyaA protein, or fragment of said CyaA protein is different between the various recombinant proteins in the mixture; and said kit of parts further comprises at least one of the following compounds; (ii) an agent, suitable for modulating a regulatory immune response in a patient ad optionally; (iii) an adjuvant component suitable for activating the innate immune response in a pa
Type:
Grant
Filed:
July 16, 2007
Date of Patent:
August 4, 2015
Assignees:
INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.